Aardvark Therapeutics, INC

Aardvark Therapeutics announced a full clinical hold by the FDA on its investigational new drug application for ARD-101, impacting Phase 3 trials for Prader-Willi Syndrome.

Aardvark Therapeutics reported Q1 2026 results, revealing a significant increase in net loss and a voluntary pause on its ARD-101 and ARD-201 programs due to cardiac observations, with further guidance expected in Q2 2026.

Aardvark Therapeutics voluntarily paused its Phase 3 ARD-101 and Phase 2 ARD-201 trials due to unexpected reversible cardiac observations in a healthy volunteer study, while reporting increased net losses for 2025.

Aardvark Therapeutics has voluntarily paused its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome due to reversible cardiac observations in a healthy volunteer study.

Aardvark Therapeutics establishes Ardia Therapeutics, a new dermatology subsidiary, and announces key leadership appointments including a new CEO for Ardia and an expanded role for its CFO.

Aardvark Therapeutics received IRB approval to lower the minimum age for its Phase 3 HERO trial of ARD-101 for Prader-Willi Syndrome from 10 to 7 years old.

Aardvark Therapeutics announced a voluntary pause in its clinical trials for ARD-101 and ARD-201 due to reversible cardiac observations in a healthy volunteer study, impacting development timelines and future guidance.

Aardvark Therapeutics reports increased R&D spending and net losses in Q3 2025, driven by clinical trial advancements for ARD-101 and ARD-201, while maintaining a strong cash position into 2027.

Aardvark Therapeutics, a clinical-stage biopharmaceutical company, reported significantly increased net losses and cash burn for Q2 2025, alongside a delay in topline data for its lead PWS drug candidate, ARD-101.

Aardvark Therapeutics announces its financial results for the first quarter of 2025, emphasizing the advancement of its Phase 3 clinical trial for ARD-101 in Prader-Willi Syndrome.

Aardvark Therapeutics has voluntarily halted enrollment and dosing in its pivotal Phase 3 HERO trial for ARD-101 and Phase 2 ARD-201 trials following reversible cardiac observations in a healthy volunteer study, leading to significant stock price decline.

Aardvark Therapeutics, a clinical-stage biopharmaceutical company, details its financial performance for 2024 and outlines key developments in its clinical programs, including the initiation of a Phase 3 trial for ARD-101.

Aardvark Therapeutics' Chief Financial Officer, Nelson Sun, was granted 70,549 stock options with an exercise price of $13.48, vesting over several years.

Aardvark Therapeutics' Chief Medical Officer, Manasi Jaiman, was granted 70,549 stock options with a $13.48 exercise price, vesting over several years.

Aardvark Therapeutics' CEO, Tien-Li Lee, was granted 203,851 stock options with an exercise price of $13.48, vesting over several years.

Aardvark Therapeutics' Chief Financial Officer, Nelson Sun, acquired 3,000 shares of common stock at $14.4 per share in a pre-planned transaction.

Aardvark Therapeutics CEO and 10% owner, Lee Tien-Li, plans to acquire 7,000 shares of common stock at $14.485 per share.

Aardvark Therapeutics CEO, Tien-Li Lee, exercised options to acquire 1,229 shares of common stock at $4.24 per share, increasing direct ownership.

Aardvark Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on August 14, 2026, with key proposals including director elections, auditor ratification, and stock option repricing.

Aardvark Therapeutics, a clinical-stage biopharmaceutical company, is seeking to raise approximately $88.9 million through an initial public offering to advance its metabolic disease therapeutics.

Aardvark Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to advance its novel therapeutics targeting metabolic diseases.

Tien-Li Lee and Jane Wu Lee have disclosed a combined beneficial ownership of 13.7% of Aardvark Therapeutics, Inc.'s common stock.

Citadel Advisors, Citadel Securities, and Kenneth Griffin have jointly filed a Schedule 13G, disclosing a combined passive beneficial ownership of 5.6% in Aardvark Therapeutics, Inc.

Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, and affiliated entities, including Dr. Xiangmin Cui, have disclosed a combined passive beneficial ownership of 18.3% in Aardvark Therapeutics, Inc.

Vickers Venture Fund VI Pte. Ltd., along with its principals Dr. Finian Tan and Christopher Michael Ho, have disclosed beneficial ownership of significant portions of Aardvark Therapeutics, Inc.'s common stock, with Vickers Pte holding 9.58%.